|
1
|
Shanthi M: Global Status Report on
Noncommunicable Diseases 2014. Geneva: WHO Press, World Health
Organization; 2014
|
|
2
|
LaVan DA, McGuire T and Langer R:
Small-scale systems for in vivo drug delivery. Nat Biotechnol.
21:1184–1191. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shi J, Xiao Z, Kamaly N and Farokhzad OC:
Self-assembled targeted nanoparticles: Evolution of technologies
and bench to bedside translation. Acc Chem Res. 44:1123–1134. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Langer R: New methods of drug delivery.
Science. 249:1527–1533. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bangham AD, Standish MM and Watkins JC:
Diffusion of univalent ions across the lamellae of swollen
phospholipids. J Mol Biol. 13:238–252. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
James ND, Coker RJ, Tomlinson D, Harris
JR, Gompels M, Pinching AJ and Stewart JS: Liposomal doxorubicin
(Doxil): An effective new treatment for Kaposi's sarcoma in AIDS.
Clin Oncol (R Coll Radiol). 6:294–296. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Green MR, Manikhas GM, Orlov S, Afanasyev
B, Makhson AM, Bhar P and Hawkins MJ: Abraxane, a novel
Cremophor-free, albumin-bound particle form of paclitaxel for the
treatment of advanced non-small-cell lung cancer. Ann Oncol.
17:1263–1268. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kamaly N, Xiao Z, Valencia PM,
Radovic-Moreno AF and Farokhzad OC: Targeted polymeric therapeutic
nanoparticles: Design, development and clinical translation. Chem
Soc Rev. 41:2971–3010. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Burgess P, Hutt PB, Farokhzad OC, Langer
R, Minick S and Zale S: On firm ground: IP protection of
therapeutic nanoparticles. Nat Biotechnol. 28:1267–1270. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Farokhzad OC and Langer R: Impact of
nanotechnology on drug delivery. ACS Nano. 3:16–20. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gulati M, Grover M, Singh S and Singh M:
Lipophilic drug derivatives in liposomes. Int J Pharm. 165:129–168.
1998. View Article : Google Scholar
|
|
12
|
Scherphof G, Roerdink F, Waite M and Parks
J: Disintegration of phosphatidylcholine liposomes in plasma as a
result of interaction with high-density lipoproteins. Biochim
Biophys Acta. 542:296–307. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Allen TM and Cleland LG: Serum-induced
leakage of liposome contents. Biochim Biophys Acta. 597:418–426.
1980. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Senior J and Gregoriadis G: Is half-life
of circulating liposomes determined by changes in their
permeability? FEBS Lett. 145:109–114. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang S-L and MacDonald RC: Acoustically
active liposomes for drug encapsulation and ultrasound-triggered
release. Biochim Biophys Acta. 1665:134–141. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ueno Y, Sonoda S, Suzuki R, Yokouchi M,
Kawasoe Y, Tachibana K, Maruyama K, Sakamoto T and Komiya S:
Combination of ultrasound and bubble liposome enhance the effect of
doxorubicin and inhibit murine osteosarcoma growth. Cancer Biol
Ther. 12:270–277. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pak CC, Erukulla RK, Ahl PL, Janoff AS and
Meers P: Elastase activated liposomal delivery to nucleated cells.
Biochim Biophys Acta. 1419:111–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meers P: Enzyme-activated targeting of
liposomes. Adv Drug Deliv Rev. 53:265–272. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gerasimov OV, Boomer JA, Qualls MM and
Thompson DH: Cytosolic drug delivery using pH- and light-sensitive
liposomes. Adv Drug Deliv Rev. 38:317–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bondurant B, Mueller A and O'Brien DF:
Photoinitiated destabilization of sterically stabilized liposomes.
Biochim Biophys Acta. 1511:113–122. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Du B, Han S, Li H, Zhao F, Su X, Cao X and
Zhang Z: Multi-functional liposomes showing
radiofrequency-triggered release and magnetic resonance imaging for
tumor multi-mechanism therapy. Nanoscale. 7:5411–5426. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arie AA and Lee JK: Effect of boron doped
fullerene C 60 film coating on the electrochemical characteristics
of silicon thin film anodes for lithium secondary batteries. Synth
Met. 161:158–165. 2011. View Article : Google Scholar
|
|
23
|
Dao TT, Matsushima T and Murata H: Organic
nonvolatile memory transistors based on fullerene and an
electron-trapping polymer. Org Electron. 13:2709–2715. 2012.
View Article : Google Scholar
|
|
24
|
Papahadjopoulos D, Jacobson K, Nir S and
Isac T: Phase transitions in phospholipid vesicles. Fluorescence
polarization and permeability measurements concerning the effect of
temperature and cholesterol. Biochim Biophys Acta. 311:330–348.
1973. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Landen CN Jr, Chavez-Reyes A, Bucana C,
Schmandt R, Deavers MT, Lopez-Berestein G and Sood AK: Therapeutic
EphA2 gene targeting in vivo using neutral liposomal small
interfering RNA delivery. Cancer Res. 65:6910–6918. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miller CR, Bondurant B, McLean SD,
McGovern KA and O'Brien DF: Liposome-cell interactions in vitro:
Effect of liposome surface charge on the binding and endocytosis of
conventional and sterically stabilized liposomes. Biochemistry.
37:12875–12883. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wolfrum C, Shi S, Jayaprakash KN,
Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K,
Ndungo EM, et al: Mechanisms and optimization of in vivo delivery
of lipophilic siRNAs. Nat Biotechnol. 25:1149–1157. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Z, Yu Y, Dai W, Lu J, Cui J, Wu H,
Yuan L, Zhang H, Wang X, Wang J, et al: The use of a tumor
metastasis targeting peptide to deliver doxorubicin-containing
liposomes to highly metastatic cancer. Biomaterials. 33:8451–8460.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Irvine DJ: Drug delivery: One
nanoparticle, one kill. Nat Mater. 10:342–343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen J, Jiang H, Wu Y, Li Y and Gao Y: A
novel glycyrrhetinic acid-modified oxaliplatin liposome for
liver-targeting and in vitro/vivo evaluation. Drug Des Devel Ther.
9:2265–2275. 2015.PubMed/NCBI
|
|
31
|
Liu Z, Xiong M, Gong J, Zhang Y, Bai N,
Luo Y, Li L, Wei Y, Liu Y, Tan X, et al: Legumain
protease-activated TAT-liposome cargo for targeting tumours and
their microenvironment. Nat Commun. 5:4280–4291. 2014.PubMed/NCBI
|
|
32
|
Davis ME, Zuckerman JE, Choi CHJ, Seligson
D, Tolcher A, Alabi CA, Yen Y, Heidel JD and Ribas A: Evidence of
RNAi in humans from systemically administered siRNA via targeted
nanoparticles. Nature. 464:1067–1070. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee JH and Lee MJ: Liposome mediated
cancer gene therapy: Clinical trials and their lessons to stem cell
therapy. Bull Korean Chem Soc. 33:433–442. 2012. View Article : Google Scholar
|
|
34
|
Felgner PL, Gadek TR, Holm M, Roman R,
Chan HW, Wenz M, Northrop JP, Ringold GM and Danielsen M:
Lipofection: A highly efficient, lipid-mediated DNA-transfection
procedure. Proc Natl Acad Sci USA. 84:7413–7417. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tari AM, Gutiérrez-Puente Y, Monaco G,
Stephens C, Sun T, Rosenblum M, Belmont J, Arlinghaus R and
Lopez-Berestein G: Liposome-incorporated Grb2 antisense
oligodeoxynucleotide increases the survival of mice bearing
bcr-abl-positive leukemia xenografts. Int J Oncol. 31:1243–1250.
2007.PubMed/NCBI
|
|
36
|
Yu L, Dean K and Li L: Polymer blends and
composites from renewable resources. Prog Polym Sci. 31:576–602.
2006. View Article : Google Scholar
|
|
37
|
Hu C-MJ, Fang RH, Copp J, Luk BT and Zhang
L: A biomimetic nanosponge that absorbs pore-forming toxins. Nat
Nanotechnol. 8:336–340. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hu C-MJ and Zhang L, Aryal S, Cheung C,
Fang RH and Zhang L: Erythrocyte membrane-camouflaged polymeric
nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci
USA. 108:10980–10985. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sinha M, Banik RM, Haldar C and Maiti P:
Development of ciprofloxacin hydrochloride loaded poly (ethylene
glycol)/chitosan scaffold as wound dressing. Nat Mater. 20:799–807.
2013.
|
|
40
|
Nguyen TTT, Ghosh C, Hwang S-G, Dai Tran L
and Park JS: Characteristics of curcumin-loaded poly (lactic acid)
nanofibers for wound healing. J Mater Sci Mater Med. 48:7125–7133.
2013. View Article : Google Scholar
|
|
41
|
Tan S, Gan C, Li R, Ye Y, Zhang S, Wu X,
Yang YY, Fan W and Wu M: A novel chemosynthetic peptide with
β-sheet motif efficiently kills Klebsiella pneumoniae in a
mouse model. Int J Nanomedicine. 10:1045–1059. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Janib SM, Moses AS and MacKay JA: Imaging
and drug delivery using theranostic nanoparticles. Adv Drug Deliv
Rev. 62:1052–1063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Grossman JH and McNeil SE: Nanotechnology
in cancer medicine. Phys Today. 65:38–42. 2012. View Article : Google Scholar
|
|
44
|
Mishra S, De A and Mozumdar S: Synthesis
of thermoresponsive polymers for drug delivery. Drug Delivery
System Clifton: Springer; pp. 77–101. 2014, View Article : Google Scholar
|
|
45
|
Gundogdu N and Cetin M: Chitosan-poly
(lactide-co-glycolide) (CS-PLGA) nanoparticles containing metformin
HCl: Preparation and in vitro evaluation. Pak J Pharm Sci.
27:1923–1929. 2014.PubMed/NCBI
|
|
46
|
Tajmir-Riahi HA, Nafisi Sh, Sanyakamdhorn
S, Agudelo D and Chanphai P: Applications of chitosan nanoparticles
in drug delivery. Methods Mol Biol. 1141:165–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Malhotra M, Tomaro-Duchesneau C, Saha S
and Prakash S: Intranasal delivery of chitosan-siRNA nanoparticle
formulation to the brain. Methods Mol Biol. 1141:233–247. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Raja MAG, Katas H and Wen Jing T:
Stability, intracellular delivery, and release of siRNA from
chitosan nanoparticles using different cross-linkers. PLoS One.
10:e01289632015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Malhotra M, Tomaro-Duchesneau C, Saha S
and Prakash S: Intranasal delivery of chitosan-siRNA nanoparticle
formulation to the brain. Drug Delivery System. Jain KK: New York,
NY: Springer; pp. 233–247. 2014, View Article : Google Scholar
|
|
50
|
Yang X, Wu S, Wang Y, Li Y, Chang D, Luo
Y, Ye S and Hou Z: Evaluation of self-assembled HCPT-loaded
PEG-b-PLA nanoparticles by comparing with HCPT-loaded PLA
nanoparticles. Nanoscale Res Lett. 9:24082014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sun C, Wang X, Zheng Z, Chen D, Wang X,
Shi F, Yu D and Wu H: A single dose of dexamethasone encapsulated
in polyethylene glycol-coated polylactic acid nanoparticles
attenuates cisplatin-induced hearing loss following round window
membrane administration. Int J Nanomedicine. 10:3567–3579.
2015.PubMed/NCBI
|
|
52
|
Rabanel J-M, Faivre J, Tehrani SF, Lalloz
A, Hildgen P and Banquy X: Effect of the polymer architecture on
the structural and biophysical properties of PEG-PLA nanoparticles.
ACS Appl Mater Interfaces. 7:10374–10385. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Diou O, Greco S, Beltran T, Lairez D,
Authelin J-R and Bazile D: A method to quantify the affinity of
cabazitaxel for PLA-PEG nanoparticles and investigate the influence
of the nano-assembly structure on the drug/particle association.
Pharm Res. 32:3188–3200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Asadi H, Rostamizadeh K, Salari D and
Hamidi M: Preparation of biodegradable nanoparticles of tri-block
PLA-PEG-PLA copolymer and determination of factors controlling the
particle size using artificial neural network. J Microencapsul.
28:406–416. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xie Y, Yi Y, Hu X, Shangguan M, Wang L, Lu
Y, Qi J and Wu W: Synchronous microencapsulation of multiple
components in silymarin into PLGA nanoparticles by an
emulsification/solvent evaporation method. Pharm Dev Technol.
21:672–679. 2016.PubMed/NCBI
|
|
56
|
Xiong W, Peng L, Chen H and Li Q: Surface
modification of MPEG-b-PCL-based nanoparticles via oxidative
self-polymerization of dopamine for malignant melanoma therapy. Int
J Nanomed. 10:2985–2996. 2015.
|
|
57
|
Zhang R, Luo K, Yang J, Sima M, Sun Y,
Janát-Amsbury MM and Kopeček J: Synthesis and evaluation of a
backbone biodegradable multiblock HPMA copolymer nanocarrier for
the systemic delivery of paclitaxel. J Control Release. 166:66–74.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang Q, Tang H and Wu P: Aqueous solutions
of poly (ethylene oxide)-poly (N-isopropylacrylamide):
Thermosensitive behavior and distinct multiple assembly processes.
Langmuir. 31:6497–6506. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
James Priya H, John R, Alex A and Anoop
KR: Smart polymers for the controlled delivery of drugs - a concise
overview. Acta Pharm Sin B. 4:120–127. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Trotta F, Dianzani C, Caldera F, Mognetti
B and Cavalli R: The application of nanosponges to cancer drug
delivery. Expert Opin Drug Deliv. 11:931–941. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hu C-MJ, Fang RH, Wang K-C, Luk BT,
Thamphiwatana S, Dehaini D, Nguyen P, Angsantikul P, Wen CH, Kroll
AV, et al: Nanoparticle biointerfacing by platelet membrane
cloaking. Nature. 526:118–121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hu CM, Fang RH, Luk BT and Zhang L:
Nanoparticle-detained toxins for safe and effective vaccination.
Nat Nanotechnol. 8:933–938. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Miele E, Spinelli GP, Miele E, Tomao F and
Tomao S: Albumin-bound formulation of paclitaxel (Abraxane ABI-007)
in the treatment of breast cancer. Int J Nanomed. 4:99–105.
2009.
|
|
64
|
Hawkins MJ, Soon-Shiong P and Desai N:
Protein nanoparticles as drug carriers in clinical medicine. Adv
Drug Deliv Rev. 60:876–885. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zheng Y-R, Suntharalingam K, Johnstone TC,
Yoo H, Lin W, Brooks JG and Lippard SJ: Pt (IV) prodrugs designed
to bind non-covalently to human serum albumin for drug delivery. J
Am Chem Soc. 136:8790–8798. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Cirstea D, Hideshima T, Rodig S, Santo L,
Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, et al:
Dual inhibition of akt/mammalian target of rapamycin pathway by
nanoparticle albumin-bound-rapamycin and perifosine induces
antitumor activity in multiple myeloma. Mol Cancer Ther. 9:963–975.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Fu Q, Sun J, Zhang W, Sui X, Yan Z and He
Z: Nanoparticle albumin-bound (NAB) technology is a promising
method for anti-cancer drug delivery. Recent Patents Anticancer
Drug Discov. 4:262–272. 2009. View Article : Google Scholar
|
|
68
|
Von Hoff DD, Mita MM, Ramanathan RK, Weiss
GJ, Mita AC, LoRusso PM, Burris HA III, Hart LL, Low SC, Parsons
DM, et al: Phase I study of PSMA-targeted docetaxel-containing
nanoparticle BIND-014 in patients with advanced solid tumors. Clin
Cancer Res. 22:3157–3163. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zuckerman JE, Gritli I, Tolcher A, Heidel
JD, Lim D, Morgan R, Chmielowski B, Ribas A, Davis ME and Yen Y:
Correlating animal and human phase Ia/Ib clinical data with
CALAA-01, a targeted, polymer-based nanoparticle containing siRNA.
Proc Natl Acad Sci USA. 111:11449–11454. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Buhleier E, Wehner W and Vögtle F:
‘Cascade’- and ‘nonskid-chain-like’ syntheses of molecular cavity
topologies. Synthesis (Mass). 155–158:19781978.
|
|
71
|
Tomalia DA, Baker H, Dewald J, Hall M,
Kallos G, Martin S, Roeck J, Ryder J and Smith P: A new class of
polymers: Starburst-dendritic macromolecules. Polym J. 17:117–132.
1985. View Article : Google Scholar
|
|
72
|
Gillies ER and Fréchet JM: Dendrimers and
dendritic polymers in drug delivery. Drug Discov Today. 10:35–43.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Kesharwani P, Jain K and Jain NK:
Dendrimer as nanocarrier for drug delivery. Prog Polym Sci.
39:268–307. 2014. View Article : Google Scholar
|
|
74
|
Khopade AJ, Caruso F, Tripathi P, Nagaich
S and Jain NK: Effect of dendrimer on entrapment and release of
bioactive from liposomes. Int J Pharm. 232:157–162. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Papagiannaros A, Dimas K, Papaioannou GT
and Demetzos C: Doxorubicin-PAMAM dendrimer complex attached to
liposomes: Cytotoxic studies against human cancer cell lines. Int J
Pharm. 302:29–38. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Purohit G, Sakthivel T and Florence AT:
Interaction of cationic partial dendrimers with charged and neutral
liposomes. Int J Pharm. 214:71–76. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Karadag M, Geyik C, Demirkol DO, Ertas FN
and Timur S: Modified gold surfaces by
6-ferrocenyl)hexanethiol/dendrimer/gold nanoparticles as a platform
for the mediated biosensing applications. Mater Sci Eng C.
33:634–640. 2013. View Article : Google Scholar
|
|
78
|
Tao X, Yang Y-J, Liu S, Zheng Y-Z, Fu J
and Chen J-F: Poly (amidoamine) dendrimer-grafted porous hollow
silica nanoparticles for enhanced intracellular photodynamic
therapy. Acta Biomater. 9:6431–6438. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yoshioka H, Suzuki M, Mugisawa M, Naitoh N
and Sawada H: Synthesis and applications of novel fluorinated
dendrimer-type copolymers by the use of fluoroalkanoyl peroxide as
a key intermediate. J Colloid Interface Sci. 308:4–10. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Zeng Y-L, Huang Y-F, Jiang J-H, Zhang X-B,
Tang C-R, Shen G-L and Yu R-Q: Functionalization of multi-walled
carbon nanotubes with poly (amidoamine) dendrimer for mediator-free
glucose biosensor. Electrochem Commun. 9:185–190. 2007. View Article : Google Scholar
|
|
81
|
Tang L, Zhu Y, Yang X and Li C: An
enhanced biosensor for glutamate based on self-assembled carbon
nanotubes and dendrimer-encapsulated platinum
nanobiocomposites-doped polypyrrole film. Anal Chim Acta.
597:145–150. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Prajapati RN, Tekade RK, Gupta U, Gajbhiye
V and Jain NK: Dendimer-mediated solubilization, formulation
development and in vitro-in vivo assessment of piroxicam. Mol
Pharm. 6:940–950. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Chauhan AS, Sridevi S, Chalasani KB, Jain
AK, Jain SK, Jain NK and Diwan PV: Dendrimer-mediated transdermal
delivery: Enhanced bioavailability of indomethacin. J Control
Release. 90:335–343. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Quintana A, Raczka E, Piehler L, Lee I,
Myc A, Majoros I, Patri AK, Thomas T, Mulé J and Baker JR Jr:
Design and function of a dendrimer-based therapeutic nanodevice
targeted to tumor cells through the folate receptor. Pharm Res.
19:1310–1316. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Liu H, Wang Y, Wang M, Xiao J and Cheng Y:
Fluorinated poly (propylenimine) dendrimers as gene vectors.
Biomaterials. 35:5407–5413. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Qiao Z and Shi X: Dendrimer-based
molecular imaging contrast agents. Prog Polym Sci. 44:1–27. 2015.
View Article : Google Scholar
|
|
87
|
Malik N, Evagorou EG and Duncan R:
Dendrimer-platinate: A novel approach to cancer chemotherapy.
Anticancer Drugs. 10:767–776. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kaminskas LM, Kelly BD, McLeod VM, Boyd
BJ, Krippner GY, Williams ED and Porter CJ: Pharmacokinetics and
tumor disposition of PEGylated, methotrexate conjugated
poly-l-lysine dendrimers. Mol Pharm. 6:1190–1204. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Al-Jamal KT, Al-Jamal WT, Wang JT-W, Rubio
N, Buddle J, Gathercole D, Zloh M and Kostarelos K: Cationic
poly-L-lysine dendrimer complexes doxorubicin and delays tumor
growth in vitro and in vivo. ACS Nano. 7:1905–1917. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Huang Z, Sengar RS, Nigam A, Abadjian MC,
Potter DM, Grotjahn DB and Wiener EC: A fluorinated dendrimer-based
nanotechnology platform: New contrast agents for high field
imaging. Invest Radiol. 45:641–654. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Yang J, Luo Y, Xu Y, Li J, Zhang Z, Wang
H, Shen M, Shi X and Zhang G: Conjugation of iron oxide
nanoparticles with RGD-modified dendrimers for targeted tumor MR
imaging. ACS Appl Mater Interfaces. 7:5420–5428. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Shi X, Wang SH, Van Antwerp ME, Chen X and
Baker JR Jr: Targeting and detecting cancer cells using
spontaneously formed multifunctional dendrimer-stabilized gold
nanoparticles. Analyst (Lond). 134:1373–1379. 2009. View Article : Google Scholar
|
|
93
|
Thomas TP, Shukla R, Kotlyar A, Liang B,
Ye JY, Norris TB and Baker JR Jr: Dendrimer-epidermal growth factor
conjugate displays superagonist activity. Biomacromolecules.
9:603–609. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Hill E, Shukla R, Park SS and Baker JR Jr:
Synthetic PAMAM-RGD conjugates target and bind to odontoblast-like
MDPC 23 cells and the predentin in tooth organ cultures. Bioconjug
Chem. 18:1756–1762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lesniak WG, Kariapper MS, Nair BM, Tan W,
Hutson A, Balogh LP and Khan MK: Synthesis and characterization of
PAMAM dendrimer-based multifunctional nanodevices for targeting
alphavbeta3 integrins. Bioconjug Chem. 18:1148–1154. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Thomas TP, Patri AK, Myc A, Myaing MT, Ye
JY, Norris TB and Baker JR Jr: In vitro targeting of synthesized
antibody-conjugated dendrimer nanoparticles. Biomacromolecules.
5:2269–2274. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Chen H-T, Neerman MF, Parrish AR and
Simanek EE: Cytotoxicity, hemolysis, and acute in vivo toxicity of
dendrimers based on melamine, candidate vehicles for drug delivery.
J Am Chem Soc. 126:10044–10048. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ahn HK, Jung M, Sym SJ, Shin DB, Kang SM,
Kyung SY, Park JW, Jeong SH and Cho EK: A phase II trial of
Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in
patients with advanced non-small cell lung cancer. Cancer Chemother
Pharmacol. 74:277–282. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Park S and Healy KE: Nanoparticulate DNA
packaging using terpolymers of poly
(lysine-g-(lactide-b-ethylene glycol)). Bioconjug
Chem. 14:311–319. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Sun T-M, Du J-Z, Yan L-F, Mao H-Q and Wang
J: Self-assembled biodegradable micellar nanoparticles of
amphiphilic and cationic block copolymer for siRNA delivery.
Biomaterials. 29:4348–4355. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Gao Y, Zhou Y, Zhao L, Zhang C, Li Y, Li
J, Li X and Liu Y: Enhanced antitumor efficacy by cyclic
RGDyK-conjugated and paclitaxel-loaded pH-responsive polymeric
micelles. Acta Biomater. 23:127–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Kohori F, Sakai K, Aoyagi T, Yokoyama M,
Sakurai Y and Okano T: Preparation and characterization of
thermally responsive block copolymer micelles comprising poly
(N-isopropylacrylamide-b-DL-lactide). J Control
Release. 55:87–98. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
He C, Zhao C, Chen X, Guo Z, Zhuang X and
Jing X: Novel pH- and temperature-responsive bock copolymers with
tunable pH-responsive range. Macromol Rapid Commun. 29:490–497.
2008. View Article : Google Scholar
|
|
104
|
Xu F, Yan T-T and Luo Y-L: Studies on
micellization behavior of thermosensitive PNIPAAm-b-PLA
amphiphilic block copolymers. J Nanosci Nanotechnol. 12:2287–2291.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Zhao C, Zhuang X, He C, Chen X and Jing X:
Synthesis of novel thermo-and pH-responsive poly (L-lysine)-based
copolymer and its micellization in water. Macromol Rapid Commun.
29:1810–1816. 2008. View Article : Google Scholar
|
|
106
|
Saravanakumar G, Lee J, Kim J and Kim WJ:
Visible light-induced singlet oxygen-mediated intracellular
disassembly of polymeric micelles co-loaded with a photosensitizer
and an anticancer drug for enhanced photodynamic therapy. Chem
Commun (Camb). 51:9995–9998. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Bae J, Maurya A, Shariat-Madar Z, Murthy
SN and Jo S: Novel redox-responsive amphiphilic copolymer micelles
for drug delivery: Synthesis and characterization. AAPS J.
17:1357–1368. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Liu Y, Li C, Wang HY, Zhang XZ and Zhuo
RX: Synthesis of thermo- and pH-sensitive polyion complex micelles
for fluorescent imaging. Chemistry. 18:2297–2304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Johnson RP, Jeong YI, John JV, Chung CW,
Kang DH, Selvaraj M, Suh H and Kim I: Dual stimuli-responsive poly
(N-isopropylacrylamide)-b-poly (L-histidine) chimeric
materials for the controlled delivery of doxorubicin into liver
carcinoma. Biomacromolecules. 14:1434–1443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zhou F, Zheng B, Zhang Y, Wu Y, Wang H and
Chang J: Construction of near-infrared light-triggered reactive
oxygen species-sensitive (UCN/SiO2-RB + DOX)@PPADT nanoparticles
for simultaneous chemotherapy and photodynamic therapy.
Nanotechnology. 27:2356012016. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wu HQ and Wang CC: Biodegradable smart
nanogels: A new platform for targeting drug delivery and biomedical
diagnostics. Langmuir. 32:6211–6225. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Moan J and Peng Q: An outline of the
hundred-year history of PDT. Anticancer Res. 23A:3591–3600.
2003.
|
|
113
|
Castano AP, Mroz P and Hamblin MR:
Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer.
6:535–545. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Krammer B: Vascular effects of
photodynamic therapy. Anticancer Res. 21B:4271–4277. 2001.
|
|
115
|
Monge-Fuentes V, Muehlmann LA and de
Azevedo RB: Perspectives on the application of nanotechnology in
photodynamic therapy for the treatment of melanoma. Nano Rev.
5:24381–24395. 2014. View Article : Google Scholar
|
|
116
|
Wang C, Cheng L and Liu Z: Upconversion
nanoparticles for photodynamic therapy and other cancer
therapeutics. Theranostics. 3:317–330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Marin E, Briceño MI and Caballero-George
C: Critical evaluation of biodegradable polymers used in nanodrugs.
Int J Nanomed. 8:3071–3090. 2013.
|
|
118
|
Ma X, Wang X, Zhou M and Fei H: A
mitochondria-targeting gold-peptide nanoassembly for enhanced
cancer-cell killing. Adv Healthc Mater. 2:1638–1643. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Jung HS, Han J, Lee J-H, Lee JH, Choi JM,
Kweon HS, Han JH, Kim JH, Byun KM, Jung JH, et al: Enhanced NIR
radiation-triggered hyperthermia by mitochondrial targeting. J Am
Chem Soc. 137:3017–3023. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Biswas S, Kumari P, Lakhani PM and Ghosh
B: Recent advances in polymeric micelles for anti-cancer drug
delivery. Eur J Pharm Sci. 83:184–202. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Dewit MA and Gillies ER: A cascade
biodegradable polymer based on alternating cyclization and
elimination reactions. J Am Chem Soc. 131:18327–18334. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Deming TJ: Synthetic polypeptides for
biomedical applications. Prog Polym Sci. 32:858–875. 2007.
View Article : Google Scholar
|
|
123
|
Sun J, Chen X, Lu T, Liu S, Tian H, Guo Z
and Jing X: Formation of reversible shell cross-linked micelles
from the biodegradable amphiphilic diblock copolymer poly
(L-cysteine)-block-poly (L-lactide). Langmuir. 24:10099–10106.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Dourado ER, Pizzorno BS, Motta LM, Simao
RA and Leite LF: Analysis of asphaltic binders modified with PPA by
surface techniques. J Microsc. 254:122–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Kim IB, Han MH, Phillips RL, Samanta B,
Rotello VM, Zhang ZJ and Bunz UH: Nano-conjugate fluorescence probe
for the discrimination of phosphate and pyrophosphate. Chemistry.
15:449–456. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Chen PC, Mwakwari SC and Oyelere AK: Gold
nanoparticles: From nanomedicine to nanosensing. Nanotechnol Sci
Appl. 1:45–65. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Huang H-C, Barua S, Sharma G, Dey SK and
Rege K: Inorganic nanoparticles for cancer imaging and therapy. J
Control Release. 155:344–357. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Namiki Y, Fuchigami T, Tada N, Kawamura R,
Matsunuma S, Kitamoto Y and Nakagawa M: Nanomedicine for cancer:
Lipid-based nanostructures for drug delivery and monitoring. Acc
Chem Res. 44:1080–1093. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Libutti SK, Paciotti GF, Byrnes AA,
Alexander HR Jr, Gannon WE, Walker M, Seidel GD, Yuldasheva N and
Tamarkin L: Phase I and pharmacokinetic studies of CYT-6091, a
novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res.
16:6139–6149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Benezra M, Penate-Medina O, Zanzonico PB,
Schaer D, Ow H, Burns A, DeStanchina E, Longo V, Herz E, Iyer S, et
al: Multimodal silica nanoparticles are effective cancer-targeted
probes in a model of human melanoma. J Clin Invest. 121:2768–2780.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Sanchez C, Belleville P, Popall M and
Nicole L: Applications of advanced hybrid organic-inorganic
nanomaterials: From laboratory to market. Chem Soc Rev. 40:696–753.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Jain RK and Stylianopoulos T: Delivering
nanomedicine to solid tumors. Nat Rev Clin Oncol. 7:653–664. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Kamaly N, Yameen B, Wu J and Farokhzad OC:
Degradable controlled-release polymers and polymeric nanoparticles:
Mechanisms of controlling drug release. Chem Rev. 116:2602–2663.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Holback H and Yeo Y: Intratumoral drug
delivery with nanoparticulate carriers. Pharm Res. 28:1819–1830.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Jain RK, Martin JD and Stylianopoulos T:
The role of mechanical forces in tumor growth and therapy. Annu Rev
Biomed Eng. 16:321–346. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Kim KY: Nanotechnology platforms and
physiological challenges for cancer therapeutics. Nanomedicine
(Lond). 3:103–110. 2007. View Article : Google Scholar
|
|
137
|
Liu D, He C, Wang AZ and Lin W:
Application of liposomal technologies for delivery of platinum
analogs in oncology. Int J Nanomed. 8:3309–3319. 2013.
|
|
138
|
Moghimi SM, Symonds P, Murray JC, Hunter
AC, Debska G and Szewczyk A: A two-stage poly
(ethylenimine)-mediated cytotoxicity: Implications for gene
transfer/therapy. Mol Ther. 11:990–995. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Lü J-M, Wang X, Marin-Muller C, Wang H,
Lin PH, Yao Q and Chen C: Current advances in research and clinical
applications of PLGA-based nanotechnology. Expert Rev Mol Diagn.
9:325–341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Kim J, Dadsetan M, Ameenuddin S, Windebank
AJ, Yaszemski MJ and Lu L: In vivo biodegradation and
biocompatibility of PEG/sebacic acid-based hydrogels using a cage
implant system. J Biomed Mater Res A. 95:191–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Nicolete R, dos Santos DF and Faccioli LH:
The uptake of PLGA micro or nanoparticles by macrophages provokes
distinct in vitro inflammatory response. Int Immunopharmacol.
11:1557–1563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Ceonzo K, Gaynor A, Shaffer L, Kojima K,
Vacanti CA and Stahl GL: Polyglycolic acid-induced inflammation:
Role of hydrolysis and resulting complement activation. Tissue Eng.
12:301–308. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Madaan K, Kumar S, Poonia N, Lather V and
Pandita D: Dendrimers in drug delivery and targeting:
Drug-dendrimer interactions and toxicity issues. J Pharm Bioallied
Sci. 6:139–150. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Jain K, Kesharwani P, Gupta U and Jain NK:
Dendrimer toxicity: Let's meet the challenge. Int J Pharm.
394:122–142. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Ma Y, Mou Q, Wang D, Zhu X and Yan D:
Dendritic polymers for theranostics. Theranostics. 6:930–947. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Dreaden EC, Austin LA, Mackey MA and
El-Sayed MA: Size matters: Gold nanoparticles in targeted cancer
drug delivery. Ther Deliv. 3:457–478. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Gu Y, Zhong Y, Meng F, Cheng R, Deng C and
Zhong Z: Acetal-linked paclitaxel prodrug micellar nanoparticles as
a versatile and potent platform for cancer therapy.
Biomacromolecules. 14:2772–2780. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Idris NM, Gnanasammandhan MK, Zhang J, Ho
PC, Mahendran R and Zhang Y: In vivo photodynamic therapy using
upconversion nanoparticles as remote-controlled nanotransducers.
Nat Med. 18:1580–1585. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Yang Y, Shao Q, Deng R, Wang C, Teng X,
Cheng K, Cheng Z, Huang L, Liu Z, Liu X, et al: In vitro and in
vivo uncaging and bioluminescence imaging by using photocaged
upconversion nanoparticles. Angew Chem Int Ed Engl. 51:3125–3129.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Chen H, Yang Z, Ding C, Chu L, Zhang Y,
Terry K, Liu H, Shen Q and Zhou J: Fragment-based drug design and
identification of HJC0123, a novel orally bioavailable STAT3
inhibitor for cancer therapy. Eur J Med Chem. 62:498–507. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Langer R and Folkman J: Polymers for the
sustained release of proteins and other macromolecules. Nature.
263:797–800. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Lee CC, MacKay JA, Fréchet JMJ and Szoka
FC: Designing dendrimers for biological applications. Nat
Biotechnol. 23:1517–1526. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Torchilin VP: Immunoliposomes and
PEGylated immunoliposomes: Possible use for targeted delivery of
imaging agents. Immunomethods. 4:244–258. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Immordino ML, Dosio F and Cattel L:
Stealth liposomes: Review of the basic science, rationale, and
clinical applications, existing and potential. Int J Nanomed.
1:297–315. 2006.
|
|
155
|
Batist G, Ramakrishnan G, Rao CS,
Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair
MK, Hoelzer K, et al: Reduced cardiotoxicity and preserved
antitumor efficacy of liposome-encapsulated doxorubicin and
cyclophosphamide compared with conventional doxorubicin and
cyclophosphamide in a randomized, multicenter trial of metastatic
breast cancer. J Clin Oncol. 19:1444–1454. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Silverman JA and Deitcher SR:
Marqibo® (vincristine sulfate liposome injection)
improves the pharmacokinetics and pharmacodynamics of vincristine.
Cancer Chemother Pharmacol. 71:555–564. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Verma J, Lal S and Van Noorden CJ:
Inorganic nanoparticles for the theranostics of cancer. Eur J
Nanomed. 7:271–287. 2015. View Article : Google Scholar
|
|
158
|
Kim MT, Chen Y, Marhoul J and Jacobson F:
Statistical modeling of the drug load distribution on trastuzumab
emtansine (Kadcyla), a lysine-linked antibody drug conjugate.
Bioconjug Chem. 25:1223–1232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Mamot C, Ritschard R, Wicki A, Stehle G,
Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R and
Rochlitz C: Tolerability, safety, pharmacokinetics, and efficacy of
doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid
tumours: A phase 1 dose-escalation study. Lancet Oncol.
13:1234–1241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Swiss Group for Clinical Cancer Research:
Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with
advanced triple negative EGFR positive breast cancer. NCT02833766.
https://clinicaltrials.gov/ct2/show/NCT02833766Accessed.
October 20–2016.
|
|
161
|
Markman M: Pegylated liposomal doxorubicin
in the treatment of cancers of the breast and ovary. Expert Opin
Pharmacother. 7:1469–1474. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Listed N: Kaposi's sarcoma: DaunoXome
approved. AIDS Treat News. 79:3–4. 1996.
|
|
163
|
Rau K-M, Lin Y-C, Chen Y-Y, Chen JS, Lee
KD, Wang CH and Chang HK: Pegylated liposomal doxorubicin
(Lipo-Dox®) combined with cyclophosphamide and
5-fluorouracil is effective and safe as salvage chemotherapy in
taxane-treated metastatic breast cancer: An open-label,
multi-center, non-comparative phase II study. BMC Cancer.
15:4232015. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
DiGiulio S: DiGiulio, S. FDA approves
onivyde combo regimen for advanced pancreatic cancer. Oncol Times.
37:82015. View Article : Google Scholar
|
|
165
|
Stathopoulos G and Boulikas T: Lipoplatin
formulation review article. J Drug Deliv. 2012:5813632012.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Ohyanagi F, Horai T, Sekine I, Yamamoto N,
Nakagawa K, Nishio M, Senger S, Morsli N and Tamura T: Safety of
BLP25 liposome vaccine (L-BLP25) in Japanese patients with
unresectable stage III NSCLC after primary chemoradiotherapy:
Preliminary results from a Phase I/II study. Jpn J Clin Oncol.
41:718–722. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Dou Y, Hynynen K and Allen C: To heat or
not to heat: Challenges with clinical translation of
thermosensitive liposomes. J Control Release. 249:63–73. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Lancet JE, Uy GL, Cortes JE, Newell LF,
Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR,
et al: Final results of a phase III randomized trial of CPX-351
versus 7+3 in older patients with newly diagnosed high risk
(secondary) AM. J Clin Oncol. 34:70002016.
|
|
169
|
Dragovich T, Mendelson D, Kurtin S,
Richardson K, Von Hoff D and Hoos A: A Phase 2 trial of the
liposomal DACH platinum L-NDDP in patients with therapy-refractory
advanced colorectal cancer. Cancer Chemother Pharmacol. 58:759–764.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Chinsriwongkul A, Chareanputtakhun P,
Ngawhirunpat T, Rojanarata T, Sila-on W, Ruktanonchai U and
Opanasopit P: Nanostructured lipid carriers (NLC) for parenteral
delivery of an anticancer drug. AAPS PharmSciTech. 13:150–158.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Strumberg D, Schultheis B, Traugott U,
Vank C, Santel A, Keil O, Giese K, Kaufmann J and Drevs J: Phase I
clinical development of Atu027, a siRNA formulation targeting PKN3
in patients with advanced solid tumors. Int J Clin Pharmacol Ther.
50:76–78. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Awada A, Bondarenko IN, Bonneterre J,
Nowara E, Ferrero JM, Bakshi AV, Wilke C and Piccart M: CT4002
study group: A randomized controlled phase II trial of a novel
composition of paclitaxel embedded into neutral and cationic lipids
targeting tumor endothelial cells in advanced triple-negative
breast cancer (TNBC). Ann Oncol. 25:824–831. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Slingerland M, Guchelaar H-J, Rosing H,
Scheulen ME, van Warmerdam LJ, Beijnen JH and Gelderblom H:
Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use
(LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil:
A randomized, two-period crossover study in patients with advanced
cancer. Clin Ther. 35:1946–1954. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Bala V, Rao S, Boyd BJ and Prestidge CA:
Prodrug and nanomedicine approaches for the delivery of the
camptothecin analogue SN38. J Control Release. 172:48–61. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Senzer NN, Matsuno K, Yamagata N, Fujisawa
T, Wasserman E, Sutherland W, Sharma S and Phan A: Abstract C36:
MBP-426, a novel liposome-encapsulated oxaliplatin, in combination
with 5-FU/leucovorin (LV): Phase I results of a Phase I/II study in
gastro-esophageal adenocarcinoma, with pharmacokinetics. Mol Cancer
Ther. 8:(Suppl. 1). C36. 2009.doi: 10.1158/1535-7163.TARG-09-C36.
View Article : Google Scholar
|
|
176
|
Seiden MV, Muggia F, Astrow A, Matulonis
U, Campos S, Roche M, Sivret J, Rusk J and Barrett E: A phase II
study of liposomal lurtotecan (OSI-211) in patients with topotecan
resistant ovarian cancer. Gynecol Oncol. 93:229–232. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Noble GT, Stefanick JF, Ashley JD,
Kiziltepe T and Bilgicer B: Ligand-targeted liposome design:
Challenges and fundamental considerations. Trends Biotechnol.
32:32–45. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Wetzler M, Thomas DA, Wang ES, Shepard R,
Ford LA, Heffner TL, Parekh S, Andreeff M, O'Brien S and Kantarjian
HM: Phase I/II trial of nanomolecular liposomal annamycin in adult
patients with relapsed/refractory acute lymphoblastic leukemia.
Clin Lymphoma Myeloma Leuk. 13:430–434. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Hwang JH, Lim MC, Seo S-S, Park S-Y and
Kang S: Phase II study of belotecan (CKD 602) as a single agent in
patients with recurrent or progressive carcinoma of uterine cervix.
Jpn J Clin Oncol. 41:624–629. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Hough B, Posner M, Chung C, et al: A phase
II study of single agent OSI-7904L in patients with metastatic or
recurrent squamous cell carcinoma of the head and neck (SCCHN).
Journal. 27:e170052009.
|
|
181
|
Pattni BS, Chupin VV and Torchilin VP: New
developments in liposomal drug delivery. Chem Rev. 115:10938–10966.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Semple SC, Leone R, Wang J, Leng EC,
Klimuk SK, Eisenhardt ML, Yuan ZN, Edwards K, Maurer N, Hope MJ, et
al: Optimization and characterization of a
sphingomyelin/cholesterol liposome formulation of vinorelbine with
promising antitumor activity. J Pharm Sci. 94:1024–1038. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Ugwu S, Zhang A, Parmar M, Miller B,
Sardone T, Peikov V and Ahmad I: Preparation, characterization, and
stability of liposome-based formulations of mitoxantrone. Drug Dev
Ind Pharm. 31:223–229. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
McMurtry V, Nieves-Alicea R, Donato N and
Tari A: Liposome-incorporated Grb2 antisense oligonucleotides as a
novel therapy against drug resistant chronic myelogenous leukemia.
Cancer Res. 68:1503. 2008.
|
|
185
|
Stathopoulos GP, Boulikas T, Kourvetaris A
and Stathopoulos J: Liposomal oxaliplatin in the treatment of
advanced cancer: A phase I study. Anticancer Res. 262B:1489–1493.
2006.
|
|
186
|
Oncology Venture: Oncology Venture
presents LiPlaCis on AACR in New Orleans. https://www.aktietorget.se/NewsItem.aspx?ID=77244
|
|
187
|
Barraud L, Merle P, Soma E, Lefrançois L,
Guerret S, Chevallier M, Dubernet C, Couvreur P, Trépo C and
Vitvitski L: Increase of doxorubicin sensitivity by
doxorubicin-loading into nanoparticles for hepatocellular carcinoma
cells in vitro and in vivo. J Hepatol. 42:736–743. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Zhou Q, Sun X, Zeng L, Liu J and Zhang Z:
A randomized multicenter phase II clinical trial of
mitoxantrone-loaded nanoparticles in the treatment of 108 patients
with unresected hepatocellular carcinoma. Nanomedicine (Lond).
5:419–423. 2009. View Article : Google Scholar
|
|
189
|
Pang X, Du H-L, Zhang H-Q, Zhai Y-J and
Zhai G-X: Polymer-drug conjugates: Present state of play and future
perspectives. Drug Discov Today. 18:1316–1322. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
QUILT-3.014: A Trial of ABI-011
administered weekly in patients with advanced solid tumors or
lymphomas. NCT02582827. https://clinicaltrials.gov/ct2/show/NCT02582827Accessed.
March 6–2017.
|
|
191
|
Giglio V, Sgarlata C and Vecchio G: Novel
amino-cyclodextrin cross-linked oligomer as efficient carrier for
anionic drugs: A spectroscopic and nanocalorimetric investigation.
RSC Advances. 5:16664–16671. 2015. View Article : Google Scholar
|
|
192
|
Svenson S: Clinical translation of
nanomedicines. Curr Opin Solid State Mater Sci. 16:287–294. 2012.
View Article : Google Scholar
|
|
193
|
Williamson SK, Johnson GA, Maulhardt HA,
Moore KM, McMeekin DS, Schulz TK, Reed GA, Roby KF, Mackay CB,
Smith HJ, et al: A phase I study of intraperitoneal nanoparticulate
paclitaxel (Nanotax®) in patients with peritoneal
malignancies. Cancer Chemother Pharmacol. 75:1075–1087. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Vergote I, Brize A, Lisyanskaya AS and
Lichinitser M: Randomized phase III study comparing
paclical-carboplatin with paclitaxel-carboplatin in patients with
recurrent platinum-sensitive epithelial ovarian cancer. J Clin
Oncol. 33:55172015.
|
|
195
|
Pitto-Barry A and Barry NP:
Pluronic® block-copolymers in medicine: From chemical
and biological versatility to rationalisation and clinical
advances. Polym Chem. 5:3291–3297. 2014. View Article : Google Scholar
|
|
196
|
Kato K, Chin K, Yoshikawa T, Yamaguchi K,
Tsuji Y, Esaki T, Sakai K, Kimura M, Hamaguchi T, Shimada Y, et al:
Phase II study of NK105, a paclitaxel-incorporating micellar
nanoparticle, for previously treated advanced or recurrent gastric
cancer. Invest New Drugs. 30:1621–1627. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Endo K, Ueno T, Kondo S, Wakisaka N,
Murono S, Ito M, Kataoka K, Kato Y and Yoshizaki T: Tumor-targeted
chemotherapy with the nanopolymer-based drug NC-6004 for oral
squamous cell carcinoma. Cancer Sci. 104:369–374. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Tsuji A, Hamaguchi T, Yamaguchi K, et al:
A phase II study of NK012, a polymeric micelle formulation of
SN-38, in colorectal cancer patients who had received prior
oxaliplatin-based regimen. Journal. 33:35272015.
|
|
199
|
Ghamande S, Lin C-C, Cho DC, Coleman T,
Chaudhary I, Shapiro GI, Silverman M, Kuo M-W, Mach WB, Tseng Y, et
al: Abstract A89: A phase I study of the novel DNA topoisomerase-1
inhibitor, TLC388 (Lipotecan®), administered
intravenously to patients with advanced solid tumors. Mol Cancer
Ther. 10:(Supplement 1). 892011. View Article : Google Scholar
|
|
200
|
Ueno T, Endo K, Hori K, Ozaki N, Tsuji A,
Kondo S, Wakisaka N, Murono S, Kataoka K, Kato Y, et al: Assessment
of antitumor activity and acute peripheral neuropathy of
1,2-diaminocyclohexane platinum (II)-incorporating micelles
(NC-4016). Int J Nanomed. 9:3005–3012. 2014. View Article : Google Scholar
|
|
201
|
Takahashi A, Yamamoto Y, Yasunaga M, Koga
Y, Kuroda J, Takigahira M, Harada M, Saito H, Hayashi T, Kato Y, et
al: NC-6300, an epirubicin-incorporating micelle, extends the
antitumor effect and reduces the cardiotoxicity of epirubicin.
Cancer Sci. 104:920–925. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Owen SC, Chan DP and Shoichet MS:
Polymeric micelle stability. Nano Today. 7:53–65. 2012. View Article : Google Scholar
|
